Markets
Web Summit 2021 - Day Two
Tarek Mansour, Co-founder, Kalshi (Photo By Diarmuid Greene/Getty Images)
No bets

No event contracts for you!

The CFTC wants to ban several event contracts, despite Americans legally betting billions on the same things.

Jack Raines

Want to bet on the 2024 presidential election? Not if the government has anything to say about it.

Last Friday, the Commodity Futures Trading Commission (CFTC) voted to propose new regulation to ban various “event contracts,” which the agency defines as “a type of derivative contract, typically with a binary payoff structure, based on the outcome of an underlying occurrence or event.”

For context, as part of the Dodd Frank Act, the CFTC has the power to prohibit certain event contracts if they 1) fall within the scope of certain “enumerated activities,” such as terrorism, assassination, war, and gaming, as well as any activity considered illegal under federal or state law, and 2) are contrary to public interest.

The CFTC is proposing that each enumerated activity be considered contrary to public interest by default, and, more importantly, that gaming should be more specifically defined to include the outcome of a political contest, the outcome of an awards contest, the outcome of a game in which one or more athletes compete, or an occurrence or non-occurrence in connection with such a contest or game.

TL;DR: events contracts for sporting events, award ceremonies, and political elections would be banned.

This isn’t the CFTC’s first conflict with the event contracts market. Seven months ago, prediction markets exchange Kalshi sued the CFTC for blocking its election contract markets.

While the CFTC claims these proposed changes are in the name of public interest, this move highlights inconsistencies in government regulation of different markets. For example, while the CFTC is trying to block event contracts related to “outcomes of games” and “awards contests,” Americans legally wagered $119 billion on sports and $185 billion in casinos in 2023. They also spent $95 billion on lottery tickets in 2021.

While event contracts differ structurally from these other examples (they are derivatives that change hands on exchanges, not one-off bets on football games, roulette wheels, or scratch off tickets), they accomplish the same goal: monetary payouts for accurate predictions. Blocking event contracts for “awards contests” and “game outcomes” while consumers already spend hundreds of billions on these very things seems inconsistent.

More Markets

See all Markets
markets

Cisco’s quarterly results beat expectations for sales and EPS

Cisco beat Wall Street expectations for sales and earnings in its fiscal second-quarter results, which it released after the close of trading Wednesday.

For the fiscal second quarter of 2026, the computer networking equipment giant reported:

  • Non-GAAP earnings per share of $1.04 vs. the $1.02 expected by Wall Street analysts, according to FactSet.

  • Sales of $15.35 billion vs. the $15.11 billion consensus expectation.

Along with other companies like Lumentum, Corning, and new S&P 500 member Ciena, which provide things like the wiring and networking equipment needed to connect server racks, Cisco shares have had a strong start to 2026 as the AI data center boom continues to roll.   

This is a developing story.

markets

McDonald's Q4 earnings, sales beat Wall Street estimates

McDonald’s reported Q4 results on Wednesday that beat Wall Street’s expectations.

For the last three months of 2025, the fast food giant reported:

  • Adjusted earnings per share of $3.12, compared to $3.05 analysts polled by FactSet were expecting.

  • Revenue at $7 billion, higher than the $6.8 billion analysts were penciling in.

  • Global comparable sales growth of 5.7%, compared to the 3.9% growth analysts were expecting.

Shares are up modestly in after-hours trading.

markets

Gilead rises after earnings beat driven by HIV drug sales

Gilead rose more than 5% on Wednesday after it reported quarterly earnings and revenue that beat Wall Street estimates, driven by sales of its HIV drugs.

For the last three months of 2025, Gilead reported:

  • Adjusted earnings per share of $1.86, compared to the $1.81 the Street was expecting.

  • $7.9 billion in revenue, more than the $7.6 billion the Street was penciling in. Late last year the company began selling Yeztugo, a twice-yearly HIV prevention shot. CEO Daniel O’Day told analysts it “has already exceeded our coverage goals and is rapidly gaining market share.”

For the full year in 2026, the company expects:

  • Adjusted earnings per share of $8.45 to $8.85, compared to the $8.79 analysts forecast.

  • Revenue of $29.6 billion to $30 billion, compared to the $29.92 billion the Street was expecting. The company anticipates Yeztugo will contribute $800 million in revenue in 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.